vs
Side-by-side financial comparison of AVNET INC (AVT) and Boston Scientific (BSX). Click either name above to swap in a different company.
AVNET INC is the larger business by last-quarter revenue ($7.1B vs $5.2B, roughly 1.4× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 1.3%, a 24.4% gap on every dollar of revenue. On growth, AVNET INC posted the faster year-over-year revenue change (12.7% vs 11.6%). Over the past eight quarters, AVNET INC's revenue compounded faster (12.7% CAGR vs 12.4%).
Avnet, Inc. is a distributor of electronic components headquartered in Phoenix, Arizona, named after Charles Avnet, who founded the company in 1921. After its start on Manhattan's Radio Row, the company became incorporated in 1955 and began trading on the New York Stock Exchange in 1961. On May 8, 2018, Avnet changed stock markets to Nasdaq, trading under the same ticker AVT.
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
AVT vs BSX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.1B | $5.2B |
| Net Profit | $94.3M | $1.3B |
| Gross Margin | 10.4% | 69.5% |
| Operating Margin | 2.9% | — |
| Net Margin | 1.3% | 25.7% |
| Revenue YoY | 12.7% | 11.6% |
| Net Profit YoY | -59.7% | — |
| EPS (diluted) | $1.14 | $0.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 26 | $7.1B | — | ||
| Q1 26 | — | $5.2B | ||
| Q4 25 | $6.3B | $5.3B | ||
| Q3 25 | $5.9B | $5.1B | ||
| Q2 25 | $5.6B | $5.1B | ||
| Q1 25 | $5.3B | $4.7B | ||
| Q4 24 | $5.7B | $4.6B | ||
| Q3 24 | $5.6B | $4.2B |
| Q3 26 | $94.3M | — | ||
| Q1 26 | — | $1.3B | ||
| Q4 25 | $61.7M | $670.0M | ||
| Q3 25 | $51.7M | $755.0M | ||
| Q2 25 | $6.1M | $795.0M | ||
| Q1 25 | $87.9M | $672.0M | ||
| Q4 24 | $87.3M | $563.0M | ||
| Q3 24 | $59.0M | $468.0M |
| Q3 26 | 10.4% | — | ||
| Q1 26 | — | 69.5% | ||
| Q4 25 | 10.5% | 69.6% | ||
| Q3 25 | 10.4% | 69.9% | ||
| Q2 25 | 10.6% | 67.7% | ||
| Q1 25 | 11.1% | 68.8% | ||
| Q4 24 | 10.5% | 67.8% | ||
| Q3 24 | 10.8% | 68.8% |
| Q3 26 | 2.9% | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 2.3% | 15.6% | ||
| Q3 25 | 2.4% | 20.7% | ||
| Q2 25 | 1.3% | 16.2% | ||
| Q1 25 | 2.7% | 19.8% | ||
| Q4 24 | 2.7% | 14.8% | ||
| Q3 24 | 2.5% | 17.4% |
| Q3 26 | 1.3% | — | ||
| Q1 26 | — | 25.7% | ||
| Q4 25 | 1.0% | 12.7% | ||
| Q3 25 | 0.9% | 14.9% | ||
| Q2 25 | 0.1% | 15.7% | ||
| Q1 25 | 1.7% | 14.4% | ||
| Q4 24 | 1.5% | 12.3% | ||
| Q3 24 | 1.1% | 11.1% |
| Q3 26 | $1.14 | — | ||
| Q1 26 | — | $0.90 | ||
| Q4 25 | $0.75 | $0.45 | ||
| Q3 25 | $0.61 | $0.51 | ||
| Q2 25 | $0.09 | $0.53 | ||
| Q1 25 | $1.01 | $0.45 | ||
| Q4 24 | $0.99 | $0.38 | ||
| Q3 24 | $0.66 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $202.4M | — |
| Total DebtLower is stronger | $2.9B | — |
| Stockholders' EquityBook value | $5.0B | — |
| Total Assets | $13.5B | — |
| Debt / EquityLower = less leverage | 0.59× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 26 | $202.4M | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $286.5M | $2.0B | ||
| Q3 25 | $175.5M | $1.3B | ||
| Q2 25 | $192.4M | $534.0M | ||
| Q1 25 | $188.9M | $725.0M | ||
| Q4 24 | $172.1M | $414.0M | ||
| Q3 24 | $267.5M | $2.5B |
| Q3 26 | $2.9B | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $11.1B | ||
| Q3 25 | — | $11.1B | ||
| Q2 25 | — | $11.1B | ||
| Q1 25 | — | $10.5B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $9.2B |
| Q3 26 | $5.0B | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $24.2B | ||
| Q3 25 | $4.8B | $23.4B | ||
| Q2 25 | $5.0B | $22.4B | ||
| Q1 25 | $4.9B | $22.2B | ||
| Q4 24 | $4.8B | $21.8B | ||
| Q3 24 | $5.0B | $20.7B |
| Q3 26 | $13.5B | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $13.2B | $43.7B | ||
| Q3 25 | $12.4B | $42.7B | ||
| Q2 25 | $12.1B | $41.6B | ||
| Q1 25 | $11.7B | $40.1B | ||
| Q4 24 | $11.9B | $39.4B | ||
| Q3 24 | $12.6B | $38.1B |
| Q3 26 | 0.59× | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.46× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVT
| Electronic Components | $6.7B | 94% |
| Farnell | $454.7M | 6% |
BSX
| Cardiovascular | $3.5B | 67% |
| Endoscopy | $736.0M | 14% |
| Urology | $646.0M | 12% |
| Neuromodulation | $318.0M | 6% |
